Intra-Cellular Therapies, Inc.
ITCI
Rangering i aksjer
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aksjekurs
$131.87
Sist synkronisert: 2025-04-02
Markedsverdi
$12.68B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Antall utestående aksjer for Intra-Cellular Therapies, Inc. (ITCI)
Antall utestående aksjer per December 2024: 103.13M
Ifølge Intra-Cellular Therapies, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 103.13M. Ved slutten av December 2023 hadde selskapet 95.88M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Intra-Cellular Therapies, Inc. (ITCI) fra 2013 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 103.13M | 0.00% |
| 2024 | 103.13M | 7.56% |
| 2023 | 95.88M | 1.95% |
| 2022 | 94.05M | 15.74% |
| 2021 | 81.25M | 15.47% |
| 2020 | 70.36M | 27.50% |
| 2019 | 55.19M | 0.87% |
| 2018 | 54.71M | 18.46% |
| 2017 | 46.18M | 6.80% |
| 2016 | 43.24M | 20.07% |
| 2015 | 36.01M | 25.69% |
| 2014 | 28.65M | 66.35% |
| 2013 | 17.22M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 2,226.49% |
IN
|
